243 related articles for article (PubMed ID: 33785864)
1. Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.
Eisenwort G; Sadovnik I; Keller A; Ivanov D; Peter B; Berger D; Stefanzl G; Bauer K; Slavnitsch K; Greiner G; Gleixner KV; Sperr WR; Willmann M; Sill H; Bettelheim P; Geissler K; Deininger M; Rülicke T; Valent P
Leukemia; 2021 Nov; 35(11):3176-3187. PubMed ID: 33785864
[TBL] [Abstract][Full Text] [Related]
2. Identification of a leukemia-initiating stem cell in human mast cell leukemia.
Eisenwort G; Sadovnik I; Schwaab J; Jawhar M; Keller A; Stefanzl G; Berger D; Blatt K; Hoermann G; Bilban M; Willmann M; Winding C; Sperr WR; Arock M; Rülicke T; Reiter A; Valent P
Leukemia; 2019 Nov; 33(11):2673-2684. PubMed ID: 30953030
[TBL] [Abstract][Full Text] [Related]
3. Phenotyping and Target Expression Profiling of CD34
Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
[TBL] [Abstract][Full Text] [Related]
4. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
Ivanov D; Milosevic Feenstra JD; Sadovnik I; Herrmann H; Peter B; Willmann M; Greiner G; Slavnitsch K; Hadzijusufovic E; Rülicke T; Dahlhoff M; Hoermann G; Machherndl-Spandl S; Eisenwort G; Fillitz M; Sliwa T; Krauth MT; Bettelheim P; Sperr WR; Koller E; Pfeilstöcker M; Gisslinger H; Keil F; Kralovics R; Valent P
Am J Hematol; 2023 May; 98(5):770-783. PubMed ID: 36814396
[TBL] [Abstract][Full Text] [Related]
6. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
[TBL] [Abstract][Full Text] [Related]
7. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
8. Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.
Sun Q; So CC; Yip SF; Wan TS; Ma SK; Chan LC
Leuk Res; 2008 Sep; 32(9):1374-81. PubMed ID: 18372040
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
[TBL] [Abstract][Full Text] [Related]
10. Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.
Moshaver B; Wouters RF; Kelder A; Ossenkoppele GJ; Westra GAH; Kwidama Z; Rutten AR; Kaspers GJL; Zweegman S; Cloos J; Schuurhuis GJ
Leuk Res; 2019 Jun; 81():27-34. PubMed ID: 31002948
[TBL] [Abstract][Full Text] [Related]
11. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
12. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
[TBL] [Abstract][Full Text] [Related]
13. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
14. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
[TBL] [Abstract][Full Text] [Related]
16. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.
Kornblau SM; Qutub A; Yao H; York H; Qiu YH; Graber D; Ravandi F; Cortes J; Andreeff M; Zhang N; Coombes KR
PLoS One; 2013; 8(10):e78453. PubMed ID: 24223100
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells in hematological disorders: current and possible new therapeutic approaches.
Annaloro C; Onida F; Saporiti G; Lambertenghi Deliliers G
Curr Pharm Biotechnol; 2011 Feb; 12(2):217-25. PubMed ID: 21044004
[TBL] [Abstract][Full Text] [Related]
19. Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
Quek L; Otto GW; Garnett C; Lhermitte L; Karamitros D; Stoilova B; Lau IJ; Doondeea J; Usukhbayar B; Kennedy A; Metzner M; Goardon N; Ivey A; Allen C; Gale R; Davies B; Sternberg A; Killick S; Hunter H; Cahalin P; Price A; Carr A; Griffiths M; Virgo P; Mackinnon S; Grimwade D; Freeman S; Russell N; Craddock C; Mead A; Peniket A; Porcher C; Vyas P
J Exp Med; 2016 Jul; 213(8):1513-35. PubMed ID: 27377587
[TBL] [Abstract][Full Text] [Related]
20. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.
Almohsen F; Al-Mudallal SS
Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):145-151. PubMed ID: 31438833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
